Phase II study of nivolumab and salvage nivolumab/ipilimumab in treatment-naïve patients with advanced non-clear cell renal cell carcinoma (HCRN GU16-260-Cohort B)

Michael B. Atkins, Opeyemi A. Jegede, Naomi B. Haas, David F. McDermott, Mehmet A. Bilen, Mark Stein, Jeffrey A. Sosman, Robert Alter, Elizabeth R. Plimack, Moshe C. Ornstein, Michael Hurwitz, David J. Peace, Sabina Signoretti, Thomas Denize, Alessia Cimadamore, Catherine J. Wu, David Braun, David Einstein, Paul J. Catalano, Hans Hammers

Cancer Epigenetics Institute
Hematology Oncology
Nuclear Dynamics and Cancer (NDC)

Georgetown University
Dana-Farber Cancer Institute
University of Pennsylvania
Beth Israel Deaconess Medical Center
Emory University
Columbia University
Northwestern University
John Theurer Cancer Center
Cleveland Clinic Foundation
Yale University
University of Illinois at Chicago
Brigham and Women's Hospital
University of Texas Southwestern Medical Center

Research output: Contribution to journal › Article › peer-review

13 Scopus citations

Sort by
Weight
Alphabetically

Phase II study of nivolumab and salvage nivolumab/ipilimumab in treatment-naïve patients with advanced non-clear cell renal cell carcinoma (HCRN GU16-260-Cohort B)

Fingerprint

Medicine and Dentistry

Nursing and Health Professions